Neuralink Receives Approval for Canadian Brain Chip Trial

Neuralink, the brain chip company founded by Elon Musk, has received Health Canada's approval to initiate its first clinical trial in Toronto, aimed at enabling individuals with quadriplegia to control devices using their thoughts. The trial will assess the safety and functionality of Neuralink's N1 Implant, which has already shown promising results in the U.S. with two patients successfully using it for tasks like gaming and 3D design. The Canadian trial, named CAN-PRIME, will last four years and will involve a specialized robotic surgical procedure. Eligible participants must be at least 19 years old and have limited movement in all four limbs. This significant step could reshape assistive technology markets and foster new innovations in healthcare. Neuralink's ongoing developments echo a broader trend of integrating technology into medical solutions to enhance human capabilities.